Full-Time

Head Account to Report & Tax Compliance

Ukie MCO

Posted on 5/15/2025

Deadline 6/14/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

No salary listed

Senior, Expert

Reading, UK

Category
Financial Accounting
Tax Accounting
Accounting
Required Skills
SAP Products
Excel/Numbers/Sheets
Requirements
  • Professional accounting qualification (CIMA/ACCA/ICAEW)
  • Degree level education or equivalent preferred
  • Very good understanding of relevant Finance process including IFRS (ie IAS 12)
  • Very good program and project management skills
  • Ability to think strategically and take a helicopter view
  • Strong delivery orientation including development of business cases
  • Problem solving and ability to exercise good business judgment
  • Very good communicator with an ability to discuss on executive level
  • Fluency in English mandatory
  • Leadership skills: ability to shape culture and motivate a large group
  • Good knowledge of the UK tax legislation including WHT, VAT
  • Excellent IT skills (Excel including VLookups, Pivot Tables etc) or SAP
  • Ability to set ambitious goals and priorities
  • Ability to work independently with minimal supervision
  • Agile and proactive
  • Positive thinking and an exceptional team player
  • Flexible in order to move forward
Responsibilities
  • Ensure a true and fair view for the financial statements for all Legal Entities under UK & Ireland perimeter
  • Accountable for the efficient, high-quality, and compliant delivery of an end-to-end A2R service
  • Collaborate closely with Europe Process Managers to support the design and implementation of key A2R projects
  • Ensures all accounts in given scope are stated in accordance with international- and local Financial Reporting Standards
  • Create, understand and apply best practices from within GFS or external best-in-class service organizations
  • Coordinates external audits in the region
  • Ensure promptly answer to Corporate and Auditors enquiries
  • Responsible for submission of all legal entity reports (accounting & Tax compliance)
  • Ensure timeliness and accuracy for Tax Returns
  • Partner with CFO on MCO head level to support business development activities
  • Partner with HUB to support IFRS / SAGA A2R activities
  • Create a culture of cooperation, collaboration and teamwork across A2R teams
  • Ensure that Compliance and Internal Control/ SOX standards are met
  • Ensure efficient, on time, high-quality HUB transition management
  • Co-ordinate the preparation of the statutory accounts for all UK and Ireland companies
  • Review required SOX controls for tax and transfer pricing issues
  • Review true ups to current and deferred tax balances
  • Validate tax payments on account for UK
  • Liaise with the Central Transfer Pricing team
  • Support UK and Ireland team on transfer pricing calculations and documentation preparation
  • Review CBCR (country by country reporting) reconciliations
Desired Qualifications
  • Proven Finance experience
  • Experience in Tax topics
  • International background with exposure to multicultural environment
  • Experience of working within a HUB / BPO model
  • Track record of having effectively managed large efficiency improvement programs

Sanofi provides healthcare solutions through the development of treatments and vaccines. The company focuses on research and development to create new medicines and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medications, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and extensive R&D efforts, supported by strategic partnerships and a diverse product pipeline. The goal of Sanofi is to enhance health outcomes and improve the quality of life for individuals globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's Q1 2025 profit grew by 20%, driven by Dupixent and new launches.
  • Tolebrutinib shows promise in treating non-relapsing secondary progressive multiple sclerosis.
  • Sanofi's investment in Innate Pharma supports pipeline execution and partnership expansion.

What critics are saying

  • Increased competition in multiple myeloma treatments may impact Sanofi's market share.
  • Integration challenges from acquisitions could pose financial risks for Sanofi.
  • Regulatory delays for tolebrutinib could affect market potential in multiple sclerosis.

What makes Sanofi unique

  • Sanofi's Sarclisa uses an innovative on-body injector for multiple myeloma treatment.
  • Acquisitions of Blueprint Medicines and Vigil Neuroscience expand Sanofi's rare disease portfolio.
  • Dupixent is the first new targeted therapy for chronic spontaneous urticaria in over a decade.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...

Quantis
Apr 24th, 2025
Innate Pharma: €15M Investment by Sanofi

Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.

Yahoo Finance
Apr 24th, 2025
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%

INACTIVE